Core Insights - FireFly Metals Ltd is advancing its Green Bay Copper-Gold Project, with a Preliminary Economic Assessment (PEA) expected to be completed in the June 2026 quarter, highlighting the project's world-scale resource potential [1][3][25]. Financial Overview - The company successfully raised approximately A$139 million in equity, which will support ongoing exploration and economic studies [4][40]. - As of December 31, 2025, FireFly had A$250.9 million in cash and liquid investments, positioning it well for aggressive drilling and development activities [3][39]. Mineral Resource Update - The total Mineral Resource at Green Bay has increased to 50.4 million tonnes (Mt) at 2.0% Copper Equivalent (CuEq) in the Measured & Indicated (M&I) categories, and 29.3 Mt at 2.5% CuEq in the Inferred category, marking a 51% increase from the previous estimate [5][7][12]. - Contained copper in the M&I category rose to 863,000 tonnes, a 113% increase, while contained gold increased to 546,000 ounces, a 174% increase [5][12]. Drilling and Exploration Progress - FireFly has completed approximately 147,000 meters of underground diamond drilling, confirming the continuity and strength of high-grade mineralization at depth [16][17]. - Exceptional drilling results include a notable intercept of 49.0 meters at 6.1% CuEq, indicating strong mineralization potential [22]. Project Development and Studies - Preparations for the resumption of mining at the Ming Mine are underway, with engineering and economic analysis ongoing to support the PEA [25][28]. - The company is also exploring funding options with potential offtake customers and export credit agencies, showing strong interest in the Green Bay concentrate [28]. Regional Exploration - FireFly is actively exploring its extensive 346 km² land package at Green Bay, with two surface drill rigs operational during the quarter [30][31]. Corporate Governance - Leanne Heywood was appointed as an Independent Non-Executive Director, bringing significant experience in the mining sector [42][44].

New customer win underscores authID’s leadership in workforce verification and stopping AI-driven hiring fraud across global enterprises Denver, Jan. 29, 2026 (GLOBE NEWSWIRE) -- authID (Nasdaq: AUID), a leading provider of biometric identity verification and authentication solutions, today announced that a global retailer of personal care products with more than $6B in annual sales has selected authID and technology partner MajorKey, an identity security organization and certified Microsoft services prov ...

Core Viewpoint - Hampton Financial Corporation has successfully closed the issuance of shares to settle debt obligations, which is expected to strengthen its balance sheet and reduce operational funding costs, positively impacting 2026 results [1] Group 1: Financial Actions - The company issued 10,528,141 subordinate voting shares to debenture holders to settle obligations under debentures totaling $4 million and a quarterly interest payment of approximately $5.2 million [1] - The shares are subject to a hold period of four months and one day, expiring on May 30, 2026 [1] Group 2: Company Overview - Hampton Financial Corporation is a private equity firm focused on building shareholder value through long-term strategic investments [2] - The company operates through its subsidiary, Hampton Securities Limited, which provides a range of services including family office, wealth management, institutional services, and capital markets activities [3] Group 3: Business Operations - Hampton Securities Limited is a full-service investment dealer regulated by CIRO and registered in multiple Canadian provinces [3] - The company offers investment banking services, including capital raising, mergers and acquisitions advisory, and assistance with listings on recognized securities exchanges [3] - Through its subsidiary, Oxygen Working Capital, the company provides factoring and commercial financing services across Canada [4]

Company Overview - Newbridge Acquisition Limited is a blank check company incorporated in the British Virgin Islands, aiming to engage in mergers, share exchanges, asset acquisitions, share purchases, recapitalizations, reorganizations, or similar business combinations with various businesses or entities [5] Initial Public Offering (IPO) Details - The company has priced its initial public offering at $10.00 per unit, offering a total of 5,000,000 units [1] - Each unit consists of one Class A ordinary share and one right, with each right entitling the holder to receive one-eighth (1/8) of a Class A ordinary share upon the completion of an initial business combination [1] - The offering is expected to close on February 2, 2026, subject to customary closing conditions [2] - The underwriters have a 45-day option to purchase up to an additional 750,000 units to cover over-allotments [2] Trading Information - The units are expected to be listed on the NASDAQ Capital Market under the ticker symbol "NBRGU" starting January 30, 2026 [1] - Once the units begin separate trading, the Class A ordinary shares and rights will be listed under the symbols "NBRG" and "NBRGR," respectively [1] Regulatory Information - A registration statement for these securities was declared effective by the SEC on September 30, 2025, with a post-effective amendment effective on December 18, 2025 [3]

LAS VEGAS, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Richtech Robotics Inc. (Nasdaq: RR), (“Richtech Robotics” or the “Company”), a Nevada-based provider of AI-driven service robots, announced today the closing of its previously announced private placement for the purchase and sale of 8,500,000 shares of the Company’s Class B common stock priced at the market under Nasdaq rules. Rodman & Renshaw LLC acted as the exclusive placement agent for the offering. The gross proceeds from the offering were approximately $38. ...

Group 1 - Altimmune, Inc. has closed a registered direct offering of 17,045,454 shares, generating approximately $75 million in gross proceeds before fees and expenses [1][2] - The funds will be used for the upcoming Phase 3 trial in metabolic dysfunction-associated steatohepatitis (MASH) and for general corporate purposes [2] - The offering was facilitated by Titan Partners, acting as the sole placement agent [3] Group 2 - Pemvidutide, Altimmune's lead candidate, is a dual-action therapy targeting glucagon and GLP-1 receptors, showing potential as a differentiated treatment for MASH [2][6] - The company has received Breakthrough Therapy Designation from the U.S. FDA for pemvidutide, indicating its significance in addressing serious liver diseases [2] - Altimmune is focused on delivering long-term value for shareholders while enhancing its operational flexibility through this investment [2]

Core Viewpoint - Alkane Resources Limited has entered into a conditional placement and earn-in agreement with Nagambie Resources Limited to explore Nagambie's gold-antimony project, aiming to target potential depth extensions through investment [1][2]. Group 1: Company Overview - Alkane Resources is an Australia-based producer of gold and antimony, operating three mines in Australia and Sweden [3][4]. - The company's assets include the Tomingley gold mine in New South Wales, the Costerfield operation in Victoria, and the Björkdal mine in Sweden, with ongoing exploration efforts to increase resources at these sites [4]. - Alkane also holds the Boda-Kaiser Project, a significant gold-copper porphyry project in New South Wales, and is actively exploring the surrounding Northern Molong Porphyry Project [5]. Group 2: Strategic Initiatives - The investment in Nagambie aligns with Alkane's strategy to grow resources and expand production capabilities [2]. - The company has identified limited deep drilling at Nagambie, which presents an opportunity for exploration and potential resource enhancement [1].

Core Viewpoint - Recordati has entered into a collaboration and license agreement with Moderna to develop and commercialize mRNA-3927, an investigational product for treating propionic acidemia, leveraging Moderna's mRNA technology and Recordati's commercial infrastructure [1][6]. Group 1: Collaboration Details - The agreement allows Moderna to lead the development of mRNA-3927, while Recordati will handle global commercialization if the product is approved [1]. - Recordati will pay Moderna an upfront payment of USD 50 million, with potential additional payments of up to USD 110 million based on development and regulatory milestones [4]. - The transaction is subject to customary closing conditions, including U.S. antitrust clearance expected within 30 days [5]. Group 2: Product Information - mRNA-3927 aims to restore propionyl-CoA carboxylase (PCC) enzyme activity in patients with propionic acidemia, a rare inherited metabolic disorder characterized by toxic metabolite buildup [2][7]. - Interim clinical data published in Nature indicates early signs of clinical improvement, with a potential data readout expected by the end of 2026 [3][10]. - mRNA-3927 is designed as a targeted disease-modifying therapy and is currently in a registrational clinical study to reduce metabolic decompensation events [3][10]. Group 3: Market Context - Propionic acidemia affects approximately 1 in 100,000-150,000 individuals globally and currently lacks effective therapies targeting the disease's root cause [7]. - The collaboration aims to address the significant unmet medical need for disease-modifying treatment options in this patient population [6].

Core Insights - Koss Corporation reported a significant decline in net sales for the second quarter of fiscal year 2026, with a decrease of 19.6% year-over-year, resulting in net sales of $2,861,379 compared to $3,557,086 in the same quarter of the previous year [2] - The company experienced a net loss of $565,407 for the second quarter, contrasting with a net income of $94,142 in the same period last year, leading to a basic and diluted net loss per share of $0.06 [2] - For the first six months of fiscal year 2026, net sales increased by 2.6% to $6,932,157, while the net loss remained relatively stable at $321,678 compared to $325,393 in the prior year [3] Sales Performance - The company saw strong sales growth in the Education market, but this was offset by a decline in European market sales due to the absence of new product launches that had previously boosted sales [4] - The direct-to-consumer (DTC) segment, which constitutes approximately 25% of total sales, grew by 13% year-over-year [4] Financial Metrics - Gross margins decreased by 260 basis points from 38.1% in the first half of fiscal year 2025 to 35.5% in the same period of fiscal year 2026, primarily due to the impact of high tariffs on products sourced from China [4] - The company reported a loss from operations of $1,014,578 for the three months ended December 31, 2025, compared to a loss of $141,784 in the same period the previous year [8] Operational Highlights - The cost of goods sold for the second quarter was $2,030,573, leading to a gross profit of $830,806, down from $1,404,957 in the same quarter of the previous year [8] - Selling, general, and administrative expenses increased to $1,845,384 for the second quarter, compared to $1,546,741 in the same period last year [8]

PASCAGOULA, Miss., Jan. 29, 2026 (GLOBE NEWSWIRE) -- HII (NYSE: HII) announced today that Fatina Brave has been appointed vice president of infrastructure and sustainability at its Ingalls Shipbuilding division. Brave succeeds Eric Crooker, who has transitioned into the role of vice president of program management at Ingalls, succeeding George Nungesser who is retiring at the beginning of February after 37 years of service to the company. Brave will oversee all environmental, health, safety, security, facil ...